Eikon Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EIKN Nasdaq 2836 eikontx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eikon Therapeutics, Inc.

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology - May 30th, 2026 12:30 pm
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology - May 21st, 2026 3:05 pm
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates - May 11th, 2026 2:01 pm
Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates - Mar 30th, 2026 5:48 am
Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls - Feb 26th, 2026 7:42 am
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering - Feb 4th, 2026 5:59 pm